Abstract:RNA interference (RNAi) provides researchers with a versatile means to modulate target gene expression. The major forms of RNAi molecules, genome-derived microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs), converge into RNA-induced silencing complexes to achieve posttranscriptional gene regulation. RNAi has proven to be an adaptable and powerful therapeutic strategy where advancements in chemistry and pharmaceutics continue to bring RNAi-based drugs into the clinic. With four siRNA medications already approved by the US Food and Drug Administration (FDA), several RNAi-based therapeutics continue to advance to clinical trials with functions that closely resemble their endogenous counterparts. Although intended to enhance stability and improve efficacy, chemical modifications may increase risk of off-target effects by altering RNA structure, folding, and biologic activity away from their natural equivalents. Novel technologies in development today seek to use intact cells to yield true biologic RNAi agents that better represent the structures, stabilities, activities, and safety profiles of natural RNA molecules. In this review, we provide an examination of the mechanisms of action of endogenous miRNAs and exogenous siRNAs, the physiologic and pharmacokinetic barriers to therapeutic RNA delivery, and a summary of the chemical modifications and delivery platforms in use. We overview the pharmacology of the four FDA-approved siRNA medications (patisiran, givosiran, lumasiran, and inclisiran) as well as five siRNAs and several miRNA-based therapeutics currently in clinical trials. Furthermore, we discuss the direct expression and stable carrier-based, in vivo production of novel biologic RNAi agents for research and development. SIGNIFICANCE STATEMENT In our review, we summarize the major concepts of RNA interference (RNAi), molecular mechanisms, and current state and challenges of RNAi drug development. We focus our discussion on the pharmacology of US Food and Drug Administration-approved RNAi medications and those siRNAs and miRNA-based therapeutics that entered the clinical investigations. Novel approaches to producing new true biological RNAi molecules for research and development are highlighted.

RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform

RNA-based Therapeutics: an Overview and Prospectus

Antisense Oligonucleotides: The State of the Art

Advances in RNA therapeutics for modulation of 'undruggable' targets

Targeting RNA structures with small molecules

Therapeutic potential and mechanism of action of oligonucleotides and ribozymes.

Innovative developments and emerging technologies in RNA therapeutics

Therapeutic Oligonucleotides: State of the Art

Small molecule approaches to targeting RNA

Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside

RNA Therapeutics - Research and Clinical Advancements

Targeting RNA with small molecules, from RNA structures to precision medicines: IUPHAR review: 40

Drug Discovery Perspectives of Antisense Oligonucleotides

Chemistry, structure and function of approved oligonucleotide therapeutics

Opportunities and challenges for antisense oligonucleotide therapies

RNA‐based medicine: from molecular mechanisms to therapy

Recent Advances and Prospects in RNA Drug Development

RNA therapy: Are we using the right molecules?

Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets

RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies

A perspective on RNA interference-based therapeutics for metabolic liver diseases